ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
Sai Parenterals Ltd submitted its 25th Annual Report for FY 2025-26 to the stock exchanges as required under SEBI (LODR) regulations.
Sai Parenterals Limited has submitted the notice for its 25th Annual General Meeting, scheduled to be held on 10th September, 2026 via video conference.
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Limited will acquire a 60% stake in Prathyuk Laboratories Private Limited for ₹15 Crore. This strategic move secures an established R&D setup in the pharma sector.
Sai Parenterals Limited will acquire a 60% equity stake in Saicriti Pharma Private Limited for ₹83.83 Crore in cash.
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals announced Q1 FY27 results, reporting standalone revenue of Rs. 56.2 crore. The company also announced acquisitions in Saicriti Pharma and Prathyak Laboratories.
Sai Parenterals Limited announced the appointment of Mr. Kunal Kakumanu as Executive Director, alongside the resignations of Mrs. Aruna Karusala and Ms. Shivali Aggarwal.
Sai Parenterals reported no deviation or variation in the utilization of IPO proceeds for the quarter ended June 30, 2026. This is a routine compliance filing.
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
Sai Parenterals has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Sai Parenterals Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulatory requirements.
Sai Parenterals Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, as required by SEBI regulations.
Sai Parenterals Ltd named Aakanksha Dubey & Co. as Secretarial Auditor and NSVR & Associates as Internal Auditor. Sai Krishna & Associates appointed Cost Auditor for 12 months.
Sai Parenterals Ltd announced the appointment of secretarial, internal and cost auditors, and authorised the MD to explore growth opportunities. The board met on 06 July 2026.
Sai Parenterals signed a ₹1,300 Crore OTC medicine supply agreement with Noumed Pharmaceuticals. The contract lasts 7.5 years with extension options.
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals secured a ₹104.50 Crore exclusive anti-TB product supply contract from Philippines-based PILL CORP. The ten-year agreement provides significant long-term revenue visibility and international market expansion.
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals reported FY26 revenue of ₹380.99 Crore, marking 140.37% growth. Robust performance was driven by CDMO exports and successful integration of its Australian subsidiary.
Sai Parenterals Limited confirmed zero deviation in utilizing its ₹285 Crore IPO proceeds. The funds were deployed across expansion, R&D, and debt repayment as planned.
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
Sai Parenterals approved audited standalone and consolidated financial results for the year ended March 31, 2026. The board meeting concluded successfully with no other material developments.
Sai Parenterals scheduled a board meeting for May 23, 2026. Directors will consider financial results for the quarter and year ended March 2026.
Sai Parenterals Limited filed its quarterly Monitoring Agency Report regarding IPO proceeds. The entire ₹285 Crore fresh issue remains unutilized in an escrow bank account.
Sai Parenterals Ltd has announced a delay in submitting its financial results for the quarter and nine months ended December 31, 2025. The delay is due to the pending audit of its recently acquired Australian subsidiary, Noumed Pharmaceuticals PTY Limited. The company expects to submit the results by May 15, 2026.
Sai Parenterals Ltd's board approved an unsecured loan of approximately ₹11.91 Crore (AUD 1.75 million) to its wholly-owned subsidiary, Sai Singapore Pte. Ltd. The funds will be used for downstream investment in Noumed Pharmaceuticals Pty Limited, Australia, which is a step-down subsidiary of the company.
Sai Parenterals Ltd has scheduled a Board Meeting on April 20, 2026, to consider a proposal for investing in or lending to its step-down Australian subsidiary, Noumed Pharmaceuticals Pty Limited. The transaction would be executed through its wholly owned subsidiary Sai Parenterals PTE Limited.